2. Chapter 29 Agents affecting blood and hematopoietic organ Chapter 29 Agents affecting blood and hematopoietic organ

3. Thrombosis – the formation of an unwanted clot within the blood vessls or heart Bleeding disorders –due to failure of hemostasis and include hemophilia and vitamin K deficiency Anemia -- caused by nutritional deficiency Dysfunctions of blood

4. Anticoagulants Antiplatelet drugs antithrombolic drugs Fibrinolytic drugs Hemostatics Agents Used in Anemia Hematopoietic growth factors Plasma volume expanders

5. Clot formation requires platelet activation and aggregation (white clot or platelet clot), followed by formation of a fibrin clot (red clot).

6. ⅫⅫaⅫa ⅪaⅪa ⅨaⅨa ⅩaⅩa Ⅲ a, Ⅶ a Ⅺ Ⅸ Ⅹ Ⅲ, Ⅶ Ⅹ + + ++ + Prothrombin( Ⅱ ) Thrombin( Ⅱ a) Fibrin ( Insoluble) Fibrin (soluble) fibrinogen ++ Ⅹ III Ⅹ IIIa + Fibrin clot process of normal blood coagulation extrinsic pathway intrinsic pathway

7. §1 anticoagulants Anticoagulants are drugs employed in preventing blood coagulation. They inhibit certain clotting factors in the liver. The function of them is to: 1) prevent the formation of new blood clots. 2) keep existing blood clots from growing larger.

8. Classification of anticoagulants Ⅰ Anticoagulants both in vivo and vitro: e.g. Heparin Ⅱ Anticoagulants in vivo: dicoumarol Ⅲ Anticoagulants in vitro: Sodium citrate

9. 1. Heparin  1.1 source and chemistry (1)large amount of negative charge (2)strong acidity

10. pharmacokinetics Absorption Administered by i.v or s.c Metabolism Excretion

11. 1.2 Pharmacological effects 1. Anticoagulative effect Mechanism: accelerate inactivation of clotting factors.( Ⅱ a, Ⅸ a, Ⅹ a, Ⅺ a, Ⅻ a ) by enhancing the anticoagulative activity of AT Ⅲ ( antithrombin Ⅲ ).

12. ⅫⅫaⅫa ⅪaⅪa ⅨaⅨa ⅩaⅩa ⅦaⅦa Ⅺ Ⅸ Ⅹ Ⅶ Ⅹ + + ++ + Prothrombin( Ⅱ ) Thrombin( Ⅱ a) Fibrin insoluble Fibrin soluble fibrinogen ++ Ⅹ III Ⅹ IIIa + Fibrin clot

13. AT Ⅲ : a plasma protease inhibitor

14. Mechanism of heparin This reaction happens in normal physiological state, but it’s very slow and weak.This reaction happens in normal physiological state, but it’s very slow and weak. In the presence of heparin (which acts as an catalyst), it will be accelerated by more than 1,000 timesIn the presence of heparin (which acts as an catalyst), it will be accelerated by more than 1,000 times

15. Characteristics of anticoagulative effect effective both in vivo and in vitro quick onset and potent effects efficacy positively relative to mocular weight

16. 1.2 Pharmacological effects 1.2 Pharmacological effects 2.Other effects  adjusting blood lipid  anti-inflammatory effect  anti-proliferative effect on vascular smooth muscle cell  inhibiting pletelet aggregation …….

17. 1.3 Clinical uses 1) thromboembolic disease: deep venous thrombosis(DVT), pulmonary embolism, unstable angina, acute myocardial infarction, cerebral infarction 2)DIC (Disseminated intravascular coagulation): early stage 3)extracorporal circulation (eg. dialysis machine)

18. 1.4 Adverse reactions Spontaneous hemorrhage : monitoring of aPTT antagonist: protamine sulfate(1mg:100u) Heparin-induced thrombocytopenia: (a decrease in circulating platelets) 2 ～ 10 days of therapy, 3%, Others : allergic reaction osteoporosis( 骨质疏松 )

19. 1.5 Contraindications: 1. Bleeding tendency: Severe hypertension Ulcer surgery of the brain,eye, spinal cord 2. pregnancy 3. Renal and hepatic dysfunctions

20. LMWHS (low molecular weight heparins) Weaker effect than heparin Low incidence of hemorrage Long-lasting effect Small individual deviation No need to monitor generally

22. Coumarin derivatives ---Oral anticoagulants These agents are often referred to as oral anticoagulants because they are administered orally, which exists as the main difference from heparin.

23. Warfarin( 华法林 ), Dicoumarin( 双香豆素 ) Acenocoumarin ( 醋硝香豆素 )

24. pharmacokinetics Absorption: rapid and complete ( warfarin ) Distribution: PPBR>90% Elimination: liver Excretion: kindney

25. 4.1 pharmacological effects Anticoagulative effect 1) mechanism: antagonizing Vit K→inhibiting the synthesis of cloting factor Ⅱ, Ⅶ, Ⅸ, Ⅹ

26. Vitamin K (reduced) Vitamin K (epoxide) warfarin Precursors of Ⅱ、Ⅶ、Ⅸ、Ⅹ mature Ⅱ、Ⅶ、Ⅸ、Ⅹ Vitamin K epo- Xide reductase

27. Mechanism of Oral anticoagulants Several clotting factors Ⅱ, Ⅶ, Ⅸ, Ⅹ ( Ⅱ, Ⅶ, Ⅸ, Ⅹ ) depend on vit K as a coenzyme in their complete synthesis by the liver. Ⅱ Oral anticoagulants antagonize VitK →inhibiting the synthesis of clotting factor Ⅱ, Ⅶ, Ⅸ, Ⅹ →inhibiting coagulation

28. 2 ) characteristics 2 ) characteristics (1) oral administration (2) effective in vivo, not in vitro (3) slow onset, long duration (4) overcome by administration of Vitamin K

29. 4.2 clinical uses: For long use Prevent acute deep vein thrombosis or pulmonary embolism  Prevent venous throboembolism in patients undergoing orthopedic or gynecological surgery  Prevent systemic embolization in patients with myocardial infarction, prosthetic heart valves or chronic atrial fibrillation

30. 4.3 adverse effects 4.3.1 Spontaneous hemorrhage : monitoring of PT ( 凝血酶原时间 ) Treatment: withdrawal of the drug; administration of vitamin K and fresh blood 4.3.2 others: birth defect (warfarin) Allergic reaction

32. 4.4 drug interactions 4.4 drug interactions 4.4.1 enzyme inducer ： barbiturates 4.4.2 competitive antagonist: Vit K 4.4.3 high PPBR: aspirin, quinidine, sulfonamide, phenylbutazone 4.4.4 enzyme inhibitor: cimetidine, isoniazid 4.4.5 PLT inhibitors: aspirin

33. Ⅲ Anticoagulants in vitro Sodium citrate, potassium oxalate Mechanism: Ca2+ Uses: prevent blood coagulation in vitro

34. §2 Fibrinolytic drugs (thrombolytic agents) §2 Fibrinolytic drugs (thrombolytic agents) These agents can activate the conversion of plasminogen to plasmin, a serine protease that hydrolyzes fibrin and thus dissolves clots. Mainly used in acute thrombolism.

35. plasminogen inhibitors － + activators plasmin ＋ + Degration fibrin splits products fibrinogen fibrin products (Fibrinolytic drugs)

36. Ⅰ Plasminogen activator from human body Urokinase (UK), Alteplase (t-PA) Ⅱ Plasminogen activator form bacteria Streptokinase (SK), Anistreplase, Stephylokinase Ⅲ Plasminogen activator from snake Snake venom antithrombus enzyme, Ancrod, Acutase

37. SHARED CHARACTERISTICS ACTION All act either direct or indirect to convert plasminogen to plasmin, which in turn cleaves fibrin, thus lysing thrombi. Clot dissolution occurs with a higher frequency when therapy is initiated early after clot formation.

38. CLINICAL USES: Used for the treatment of deep-vein thrombosis, serious pulmonary embolism, acute myocardial infarction, peripheral arterial thrombosis, etc.

39. 1. Streptokinase(SK) 1.1 mechanism: acts indirectly SK-plasminogen complex → activate plasminogen 1.2 clinical uses: thrombolytic therapy: early,< 6h intravenous route: DVT, multiple pulmonary emboli intra-arterial route: myocardial infarction 1.3 adverse reactions: bleeding, hypotension, allergic reaction

40. plasminogen inhibitors － + SK- plasminogen complex plasmin ＋ + Degration fibrin splits products fibrinogen fibrin products

41. 2. Urokinase(UK) mechanism: activating plasminogen directly clinical uses: Same use as SK, especially cerebral embolism adverse reactions: bleeding, but no antigenicity

42. plasminogen inhibitors － + UK plasmin ＋ + Degration fibrin splits products fibrinogen fibrin products

43. 3.tissue plasminogen activator (t-PA) Mechanism: act directly Charateristics: act selectively, risk of bleeding ↓ (High affinity to plasmnogen bound to fibrin in the embolism ， low affinity to free plasmnogen) superior to SK and UK

44. 4. anistreplase (anisoylated plasminogen streptokinase activator complex) a complex of purified human plasminogen and bacterial streptokinase that has been acylated to protect the enzyme’s active site. When administered, the acyl group spontaneously hydrolyzes, activating streptokinase-proactivator complex. greater clot selectivity (ie, more activity on plasminogen associated with clots than on free plasminogen in the blood)

45. §3 antiplatelet drugs

46. Antipletelet drug---- Drug that inhibits platelets from aggregating to form a plug. They are used to prevent clotting and alter the natural course of atherosclerosis.

47. Platelets activation processes involve three steps: 1.adhesion to the site of injury 2.release of intracellular granules 3.aggregation of the platelets.

49. Classification Ⅰ Inhibitors of platelet metabolism Ⅱ Agents inhibting platelet activity induced by ADP: Ticlopidine Ⅲ Thrombin inhibitor: argatroban IV GPΠb / Шa receptor blocker: abciximab

50. AA TXA 2 ( － ) ( ＋ ) AC AC PDE cAMP ↓ cAMP↑ 5-AMP ↑aggregation ↓aggregation (PLT) (endothelium) aspirin s - Dipyridamole - + aspirin l COX - PGI 2

51. Ⅰ Inhibitors of platelet metabolism ⅰ Cyclooxygenase inhibitors: Aspirin ⅱ PDE inhibitors : Dipyridamole ⅲ TXA2 synthetase inhibitor: Ridogrel ⅳ Activators of adenylate cyclase: epoprostenol (PGI2)

52. ⅰ Cyclooxygenase inhibitors: Aspirin Aspirin is a classic old drug which is used as a NSAIDs for more than 100 years. Besides antipyretic, analgesic and anti- inflammatory activities, it can inhibit platelet aggregation.

53. Pay attention! at small dose (50 ～ 75mg/d) ： inhibit the synthesis of TXA2 – which causes platelet aggregation at higher doses (> 320 mg/day) ： inhibits the synthesis of PGI2 – which inhibits platelet aggregation.

54. Clinical Uses Clinical Uses  Prophylaxis after cardiac operation  to reduce the incidence of recurrent myocardial infarction (MI)  Prophylaxis for transient ischemic attacks (TIA) or post TIA

55. ⅱ PDE inhibitors : Dipyridamole Mechanism : 1) ↓PDE → cAMP ↑ ↓ aggregation 2) ↓ the uptake of adenosine →↑AC Clinical use: Substitute of aspirin prosthetic heart valves, etc.

56. ⅲ TXA2 synthetase inhibitor: Ridogrel More effective than aspirin Fewer adverse reaction

58. Ⅱ Agents inhibting platelet activity induced by ADP: Ticlopidine Broad spectrum inhibitor of PLT aggregation Mechanism: disturb the release of α-granule and binding of fibrin to GP Ⅱ b/ Ⅲ a receptor induced by ADP Clinic use: thromboembolic disease Severe toxicity: nausea, bone marrow depression

59. Ⅲ Thrombin inhibitor: Argatroban Thrombin inhibitor has a short half-life, is given by continuous intravenous infusion, and monitoring is done by aPTT. Its clearance is not affected by renal disease but is dependent on liver function.

60. hirudin irreversible thrombin inhibitor from the leech now available in recombinant form as lepirudinin. has a short half-life, but it accumulates in renal insufficiency and no antidote exists. Mainly used after surgery

61. IV GPΠb / Шa receptor blocker: abciximab ( 阿昔单抗 ) activation of glycoprotein receptor on PLT membrane is the final common pathway for platelet aggregation. Mechanism: blockade of glycoprotein receptors on PLT membrane

62. §4 Hemostatics

63. Ⅰ Coagulants Vitamin K Ⅱ Antifibrinolytic drugs Tranexamic acid Aminomethylbenzoic acid Ⅲ Thrombin Ⅳ Vasoconstrictors Etamsylate Posterior pituitary( 垂体后叶素 )

64. ⅰ Vitamin K [Source and types] Vitamin K is found in meats, dairy products, leafy green vegetables Two natural forms : VitK1,VitK2 Two synthesized forms: VitK3,VitK4

65. Mechanism of vitamin K Ⅱ, Ⅶ, Ⅸ, Ⅹ Smoe clotting factors ( Ⅱ, Ⅶ, Ⅸ, Ⅹ ) that are involved in the coagulation reactions depend on vitamin K as a coenzyme in their complete synthesis by the liver.

66. ⅫⅫaⅫa ⅪaⅪa ⅨaⅨa ⅩaⅩa ⅦaⅦa Ⅺ Ⅸ Ⅹ Ⅶ Ⅹ + + ++ + Prothrombin( Ⅱ ) Thrombin( Ⅱ a) Fibrin insoluble Fibrin soluble fibrinogen ++ Ⅹ III Ⅹ IIIa + Fibrin clot

67. Clinical uses: Hemorrage resulting from VitK deficiency 1) Excess of oral anticoagulants 2) Obstructive jaundice and biliary fistula (vitamin K is a fat-soluble vitamin ) 3) long term use of broad spectrum antibiotics: (some vitamin K is synthesized by intestinal bacteria.) 4) Prevent hemorrhage in newborn baby and premature infants.

68. Ⅱ Anti-fibrinolysin( 抗纤溶剂 ) Aminomethylbenzoic acid Mechanism: 1) inhibit plasminogen activation 2) inhibit the activity of plasmin (large dose) Clinical uses bleeding due to high activity of plasmin Adverse reactions intravascular thrombosis

69. plasminogen inhibitors － + activators (Anti-fibrinolysin) plasmin ＋ + Degration fibrin splits products fibrinogen fibrin products

70. Ⅲ Thrombin (Factor Ⅱ ) Extracted from animal blood Activate firinogen to fibrin Used to stop bleeding or hemorrhage.

71. §5 Agents Used in Anemia Anemia ---a deficiency in erythrocytes or hemoglobin. Normal value RBC(104/μL) Hb(g/dL) Adult male 12~16 400~550 Adult famale 11~15 350~500

72. Types of anemia Iron-deficiency anemia megaloblastic anemia aplastic anemia hemolytic anemia

73. 1. Iron p.o.: Ferrous sulfate （硫酸亚铁） Ferric ammonium citrate （枸橼酸铁铵） Ferrous fumarate （富马酸亚铁） i.m.: Iron dextran

74. Pharmacokinetics: Pharmacokinetics: Absorption: Fe2+ Increase: Vitamin C, amino acid, gastric acid Decrease: phosphorus, calcium ， Tannic acid, Antacids, H 2 -receptor blockers, Proton pump inhibitors, Tetracyclines

75. Transfer: transferrin Utilization: transferrin-R on proliferating erythroid cells. Storage: ferritin(Fe3+) in intestinal mucosal cells and in macrophages in the liver, spleen, and bone.

76. Pharmacological actions: Iron is part of hemoglobin, the oxygen- carrying component of the blood. Iron- deficient people tire easily because their bodies are starved for oxygen. Iron is also part of myoglobin. Myoglobin helps muscle cells store oxygen.

77. Clinical uses: treatment or prevention of iron deficiency anemia 1) chronic blood loss in heavy menstrution or hemorrhoid 2) insufficient intake during periods of accelerated growth in children, or in pregnant women. 10~14d 4~8w 2~3m

78. Adverse reactions Adverse reactions 1) p.o. : marked gastrointestinal irritation 2) i.m. : remarkable local irritation 3) acute iron toxicity: >1g gastric irrigation→shock→death lavage: phosphate or carbonate deferoxamine: a potent iron chelating compound

79. 2. Folic acidFolic acid Process in body FA → FH2 → FH4 → 5-CH3-FH4 Machinism: One carbon unit carrier ☆ Reduction of folic acid → ↓dTMP →↓ DNA→megaloblastic anemia ↓amino acid biosynthesis

81. Clinical uses: 1. Megaloblastic anemia 2. Pernicious anemia 3. Megaloblastic anemia caused by FH2 reductase inhibitors: methotrexate, Pyrimethamine ( 乙嘧啶, 息疟定 ) Calcium Leucovorin ( not for regular deficiency )

82. 3. Vitamin B12 Source: Meat (especially liver), eggs, and dairy products. Pharmacokinetics: Requirements of Vitamin B12: 1μg/d Absorption: intrinsic factor Storage: in liver

83. Pharmacological Action: 1) methyl transfer pernicious anemia 2) isomerization of methylmalonyl-CoA to succinyl-CoA destroy integrity of myelin sheath→ nerve damage TAC dTMPdUMP

84. Clinical uses: 1. Megaloblastic anemia 2.Pernicious anemia 3.Nervous system diseases 4. Hepatopathy

85. Section 6 Hematopoietic growth factors Erythropoietin (EPO) Granulocyte colony-stimulating factor (G-CSF) Granulocyte-macrophage colony- stimulating factor (GM-CSF)

86. Erythropoietin (EPO) source: produced by the kidney in response to tissue hypoxia. Pharmacological effects: stimulates erythroid proliferation and differentiation Stimulates maturation of red blood cell also induces release of reticulocytes from the bone marrow

87. Clinical uses: patients with chronic renal failure patients with aplastic anemia anemias associated with chronic inflammation, AIDS, and cancer Adverse reaction: a rapid increase in hemoglobin hypertension and thrombotic complications.

88. Granulocyte colony-stimulating factor (G-CSF) Pharmacological effects: stimulates proliferation and differentiation of progenitors to neutrophils Increase release of neutrophils from bone marrow activates the phagocytic activity of mature neutrophils and prolongs their survival in the circulation. Clinical uses: neutropenia

89. Granulocyte-macrophage colony- stimulating factor (GM-CSF) Pharmacological effects: stimulates proliferation and differentiation of early and late granulocytic progenitor cells as well as erythroid and megakaryocyte progenitors stimulates the function of mature neutrophils Clinical uses: neutropenia Adverse reaction: fevers, malaise, arthralgias, myalgias, peripheral edema and pleural or pericardial effusions, allergic reactions

90. Section 7 Plasma volume expanders Used to replace or maintain blood vol Charactristics: –↑ plasma Osmotic pressure – Slowly eliminated – Not toxic – No antigenicy

91. dextran Dextran 70 (medium molecular dextran) Dextran 40 (low molecular dextran) Dextran 10 (small molecular dextran)

92. Pharmacological actions Increase plasma Osmotic pressure ↑ blood volume ( dextran 70 > dextran 40 >dextran 20 ) Anti-coagulative effect: ↓aggregation of red blood cell, platelet ; inhibit clotting factor Ⅱ ; improve microcirclation Osmotic diuretic effect

93. Clinical uses hypovolemic shock Thrombolic disease Adverse reaction Alergic effect Dysfunction of blood coagulation AHF